+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Prostate Cancer Therapeutics Market by Therapeutic Mechanism, Therapy Line, Formulation, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896567
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Prostate Cancer Therapeutics Market grew from USD 10.62 billion in 2024 to USD 11.32 billion in 2025. It is expected to continue growing at a CAGR of 6.34%, reaching USD 15.37 billion by 2030.

Pioneering Frontiers in Prostate Cancer Therapeutics

Prostate cancer remains a critical focus within oncology, accounting for significant morbidity and mortality worldwide. Rapid advances in molecular biology and immunology have catalyzed the development of novel agents, transforming the therapeutic landscape. The interplay of innovative modalities-from targeted therapies to precision immunotherapies-underscores the urgency for stakeholders to stay informed and agile.

This executive summary distills the most salient developments, offering a panoramic view of recent breakthroughs, regulatory shifts, and emerging challenges. It provides a coherent narrative designed to support strategic planning and investment decisions across the value chain, emphasizing how these changes converge to reshape patient outcomes and market dynamics.

By presenting core insights without market sizing or projections, this summary equips decision-makers with a clear understanding of the current environment. It highlights critical inflection points and identifies areas for future exploration, laying the groundwork for more detailed analysis. As the oncology community navigates an era of unprecedented innovation, this introduction sets the stage for a deeper examination of transformative trends, policy impacts, and strategic imperatives that will define prostate cancer therapeutics in the years ahead.

Redrawing the Prostate Cancer Landscape with Breakthrough Therapies

A paradigm shift is underway in prostate cancer care, driven by advances that transcend incremental improvements. Traditional chemotherapy regimens are being refined through targeted combinations, while next-generation antiandrogens and CYP17 inhibitors are redefining hormone therapy by delivering enhanced specificity and reduced toxicity. Simultaneously, radiopharmaceuticals have evolved with alpha emitters offering superior tumor targeting compared to their beta counterparts, signaling a new era of precision in treatment delivery.

Immunotherapy has emerged as a transformative force, with checkpoint inhibitors reinvigorating T-cell responses and cancer vaccines poised to prime the immune system earlier in the disease course. Meanwhile, cell therapies are pushing the boundaries of adoptive immunotherapy, demonstrating potential to achieve durable remissions in select patient populations. Complementing these modalities, targeted therapies such as PARP inhibitors and tyrosine kinase inhibitors are seamlessly integrated into combination regimens, addressing resistance mechanisms and enhancing therapeutic efficacy.

These shifts collectively represent a move toward personalized oncology, where molecular profiling and biomarker-driven approaches guide treatment selection. This evolution demands cross-disciplinary collaboration among clinicians, researchers, and payers. By understanding these transformative developments, industry leaders can anticipate market needs, align R&D investments, and forge partnerships that accelerate the translation of scientific discoveries into clinical practice.

Navigating the Ripple Effects of 2025 Tariffs on US Prostate Cancer Treatment

The implementation of tariffs on pharmaceutical imports in 2025 has introduced a complex set of cost dynamics that reverberate throughout the prostate cancer supply chain. Manufacturers are assessing alternative sourcing strategies to mitigate increased input expenses, while contract negotiations with key stakeholders are being recalibrated to accommodate evolving pricing pressures. This landscape compels organizations to reevaluate procurement protocols and explore nearshoring opportunities to secure critical active ingredients and finished products.

Consequently, treatment centers and specialty clinics are facing increased operational costs that may influence formulary decisions. Payers are scrutinizing reimbursement frameworks more closely, pressing for value-based agreements that align pricing with patient outcomes. These negotiations underscore the importance of demonstrating real-world effectiveness, as therapeutics are benchmarked against both clinical trial data and post-market performance.

Amid these challenges, proactive risk management strategies are emerging. Companies are leveraging advanced analytics to forecast tariff impacts across different supply chain nodes and are engaging in strategic hedging to stabilize budgets. Collaborative alliances between manufacturers and distributors are also being forged to share logistical efficiencies and optimize inventory levels. By understanding the multifaceted effects of the 2025 tariffs, stakeholders can craft resilient business models that sustain innovation and ensure patient access to lifesaving therapies.

Unveiling Market Dynamics Through Deep-Dive Segmentation Analysis

Dissecting market behavior through therapeutic mechanism reveals that chemotherapy regimens, encompassing antimetabolites, platinum compounds, and taxanes, continue to serve as foundational options, yet are increasingly complemented by precision hormone therapies. Antiandrogens, CYP17 inhibitors, GnRH agonists, and antagonists are now integral for managing disease progression with tailored approaches. Immunotherapy segments such as cancer vaccines, cell therapies, and checkpoint inhibitors are gaining traction, offering promising avenues for durable responses. Radiopharmaceuticals, divided into alpha and beta emitters, are reshaping clinical protocols by providing targeted radiation delivery with minimized systemic exposure. Targeted therapies including monoclonal antibodies, PARP inhibitors, and tyrosine kinase inhibitors are establishing new efficacy benchmarks through molecularly driven mechanisms.

Examining therapy line stratification highlights the differentiated needs of patients receiving first-line, second-line, and later-line treatments. Leaders are optimizing sequencing strategies to maximize therapeutic windows and prolong survival. Formulation preferences between injectable and oral administration modes reflect a growing emphasis on convenience, compliance, and outpatient care models. Distribution channel analysis demonstrates the rising influence of hospital pharmacies, online dispensing platforms, and retail outlets in expanding patient access and streamlining supply logistics. Finally, the end-user landscape, encompassing cancer centers, homecare providers, hospitals, and specialty clinics, underscores the need for customizable service offerings and support programs that address diverse care settings. Together, these segmentation insights illuminate pathways for targeted investments and strategic differentiation.

Regional Nuances Driving Prostate Cancer Treatment Adoption Worldwide

Across the Americas, robust research infrastructure and well-established reimbursement systems have fostered rapid adoption of cutting-edge therapeutics, with an emphasis on value-based care models. Market entry strategies here prioritize payer negotiations and real-world evidence generation to justify premium pricing. In Europe, Middle East & Africa, heterogeneity in healthcare funding and regulatory pathways creates both challenges and opportunities. Adaptive trial designs and regional partnerships are instrumental in navigating diverse approval processes while addressing access inequities.

In the Asia-Pacific region, demographic trends and rising healthcare expenditure are driving an accelerated uptake of innovative treatments, yet market penetration varies significantly across mature markets such as Japan and emerging economies like India. Strategic alliances with local stakeholders, together with tiered pricing approaches, are critical to balancing affordability and market growth.

These regional nuances compel companies to adopt flexible go-to-market strategies that reflect local healthcare landscapes. By tailoring product portfolios, clinical programs, and stakeholder engagement plans to the unique characteristics of each region, organizations can optimize market entry sequences, streamline compliance efforts, and ultimately expand patient access to transformative therapies.

Strategic Profiles of Leading Innovators in Prostate Cancer Therapeutics

Leading companies are leveraging differentiated portfolios and collaborative research to maintain a competitive edge. Established pharmaceutical firms are reinforcing their pipelines through strategic acquisitions and co-development agreements, particularly in immuno-oncology and targeted radiopharmaceuticals. Biotech innovators are capitalizing on niche biomarkers to advance novel cell therapies and bispecific antibodies, drawing significant venture capital interest and forging partnerships to scale manufacturing capabilities.

Several players are establishing centers of excellence that integrate translational research with clinical trial networks, accelerating the bench-to-bedside trajectory. Collaborative consortia between industry and academic institutions are enhancing patient recruitment and enabling adaptive study designs that respond to emerging data in real time. Additionally, digital health initiatives are being embedded within therapeutic offerings, encompassing remote monitoring, adherence tracking, and patient support platforms to improve outcomes and differentiate brands.

Competitive maneuvering has also intensified around label expansions and life-cycle management, as companies seek to extend indications into earlier disease stages and combination regimens. Regulatory designations, such as breakthrough therapy and priority review, are being pursued to expedite approvals and secure market exclusivity. This dynamic environment underscores the importance of agility, scientific leadership, and strategic collaborations in defining the next wave of market leaders.

Strategic Imperatives to Propel Growth in Prostate Cancer Therapeutics

Industry leaders must prioritize integrated R&D programs that bridge basic science with clinical validation, ensuring that novel mechanisms translate into meaningful patient benefits. Establishing multidisciplinary teams that encompass translational researchers, health economists, and regulatory experts will expedite product development and optimize trial designs. Moreover, forging strategic partnerships with technology firms can enhance digital health integration, providing real-time insights into patient adherence and therapeutic outcomes.

To mitigate emerging tariff-related risks, organizations should diversify supply chains and invest in regional manufacturing hubs. Engaging early with payers to co-create value-based reimbursement models will strengthen market positioning and facilitate access negotiations. Additionally, adopting flexible pricing frameworks that reflect regional economic disparities can expand reach in underserved markets while preserving profitability.

Finally, companies should embed sustainability and health equity principles within their strategies. Implementing patient assistance programs and community outreach initiatives will foster trust and improve care delivery. By aligning commercial objectives with social responsibility, industry leaders can catalyze long-term growth and ensure that innovations in prostate cancer therapeutics achieve their full potential.

Robust Research Framework Underpinning Market Insights

This analysis is grounded in a multi-phased research framework that integrates qualitative and quantitative methodologies. Primary research comprised in-depth interviews with oncologists, payers, supply chain experts, and patient advocacy groups to capture firsthand perspectives on clinical practice trends, reimbursement challenges, and patient needs. Secondary research involved systematic reviews of peer-reviewed literature, regulatory filings, company disclosures, and industry databases to validate emerging scientific and commercial developments.

Data triangulation techniques were deployed to reconcile disparate insights and ensure robustness of findings. Competitive benchmarking assessed organizational strategies, product portfolios, and partnership landscapes. Scenario analyses were conducted to evaluate potential impacts of policy changes, such as the 2025 US tariffs, on supply chain dynamics and pricing frameworks.

Geographic segmentation was informed by regional healthcare infrastructure, regulatory environments, and market maturity indices. Therapeutic mechanism and therapy line segmentations were analyzed through treatment utilization studies and clinical guidelines. Formulation and distribution channel insights were derived from prescribing patterns and pharmacy dispensing data. End-user insights incorporated surveys of treatment centers, homecare providers, hospitals, and specialty clinics to assess service delivery models.

Rigorous validation workshops with key stakeholders were held to refine conclusions and recommendations, ensuring relevance and applicability for decision-makers across the prostate cancer ecosystem.

Synthesis of Key Insights for Informed Decision-Making

This executive summary has illuminated critical advancements and challenges shaping the prostate cancer therapeutic arena. From the emergence of precision immunotherapies and radiopharmaceutical innovations to the strategic responses required by the 2025 tariff landscape, stakeholders are operating in an environment characterized by rapid evolution and complex interdependencies.

Deep-dive segmentation analysis has underscored the importance of aligning product development and commercialization strategies with nuanced market preferences across therapeutic mechanisms, therapy lines, formulations, distribution channels, and end users. Regional insights highlight the need for tailored approaches to navigate diverse regulatory frameworks and healthcare infrastructures. Competitive intelligence reveals that agility, collaborative R&D, and digital integration are key differentiators among leading organizations.

Actionable recommendations emphasize the imperative for integrated research programs, supply chain diversification, value-based reimbursement models, and a steadfast commitment to health equity. By synthesizing these insights, decision-makers are equipped to chart a course that balances innovation with practical considerations of cost, access, and patient outcomes.

As the field of prostate cancer therapeutics continues to advance, the strategic application of these findings will be instrumental in driving both clinical progress and market success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Mechanism
    • Chemotherapy
      • Antimetabolites
      • Platinum Compounds
      • Taxanes
    • Hormone Therapy
      • Antiandrogens
      • CYP17 Inhibitors
      • GnRH Agonists
      • GnRH Antagonists
    • Immunotherapy
      • Cancer Vaccines
      • Cell Therapy
      • Checkpoint Inhibitors
    • Radiopharmaceuticals
      • Alpha Emitters
      • Beta Emitters
    • Targeted Therapy
      • Monoclonal Antibodies
      • Parp Inhibitors
      • Tyrosine Kinase Inhibitors
  • Therapy Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • Formulation
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Cancer Centers
    • Homecare Providers
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism
8.1. Introduction
8.2. Chemotherapy
8.2.1. Antimetabolites
8.2.2. Platinum Compounds
8.2.3. Taxanes
8.3. Hormone Therapy
8.3.1. Antiandrogens
8.3.2. CYP17 Inhibitors
8.3.3. GnRH Agonists
8.3.4. GnRH Antagonists
8.4. Immunotherapy
8.4.1. Cancer Vaccines
8.4.2. Cell Therapy
8.4.3. Checkpoint Inhibitors
8.5. Radiopharmaceuticals
8.5.1. Alpha Emitters
8.5.2. Beta Emitters
8.6. Targeted Therapy
8.6.1. Monoclonal Antibodies
8.6.2. Parp Inhibitors
8.6.3. Tyrosine Kinase Inhibitors
9. Prostate Cancer Therapeutics Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line and Beyond
10. Prostate Cancer Therapeutics Market, by Formulation
10.1. Introduction
10.2. Injectable
10.3. Oral
11. Prostate Cancer Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Prostate Cancer Therapeutics Market, by End User
12.1. Introduction
12.2. Cancer Centers
12.3. Homecare Providers
12.4. Hospitals
12.5. Specialty Clinics
13. Americas Prostate Cancer Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Prostate Cancer Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Prostate Cancer Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Astellas Pharma Inc.
16.3.2. Pfizer Inc.
16.3.3. Johnson & Johnson
16.3.4. F. Hoffmann-La Roche AG
16.3.5. Novartis AG
16.3.6. Bayer AG
16.3.7. AstraZeneca PLC
16.3.8. Sanofi S.A.
16.3.9. Bristol-Myers Squibb Company
16.3.10. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PROSTATE CANCER THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PROSTATE CANCER THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PROSTATE CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PROSTATE CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 71. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 72. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 73. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 74. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 75. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 76. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 77. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 81. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 82. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 132. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 133. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 134. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 135. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 137. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 142. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 144. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 147. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 162. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 163. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 164. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 166. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 167. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 168. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 169. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 172. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 173. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 174. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 179. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 212. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 213. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 217. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 219. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. DENMARK PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 232. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 234. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 236. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 237. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 238. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 239. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. QATAR PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 242. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 244. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 245. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 247. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. FINLAND PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 272. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 273. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 274. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 277. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 279. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. EGYPT PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 282. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 284. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 285. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 286. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 287. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 289. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. TURKEY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 302. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 303. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 304. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 307. NORWAY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 308. NORWAY PROSTAT

Companies Mentioned

The companies profiled in this Prostate Cancer Therapeutics market report include:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Table Information